Your browser doesn't support javascript.
loading
The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients.
Khan, Nabeel; Patel, Dhruvan; Pernes, Tyler; Patel, Manthankumar; Trivedi, Chinmay; Medvedeva, Elina; Xie, Dawei; Yang, Yu-Xiao.
Afiliação
  • Khan N; Corporal Michael J Crescenz VA Medical Center, Department of Gastroenterology, Philadelphia, Pennsylvania, USA.
  • Patel D; University of Pennsylvania, Perelman School of Medicine, Department of Medicine, Philadelphia, Pennsylvania, USA.
  • Pernes T; University of Pennsylvania, Perelman School of Medicine, Department of Gastroenterology, Philadelphia, Pennsylvania, USA.
  • Patel M; Corporal Michael J Crescenz VA Medical Center, Department of Gastroenterology, Philadelphia, Pennsylvania, USA.
  • Trivedi C; Corporal Michael J Crescenz VA Medical Center, Department of Gastroenterology, Philadelphia, Pennsylvania, USA.
  • Medvedeva E; Corporal Michael J Crescenz VA Medical Center, Department of Gastroenterology, Philadelphia, Pennsylvania, USA.
  • Xie D; Corporal Michael J Crescenz VA Medical Center, Department of Gastroenterology, Philadelphia, Pennsylvania, USA.
  • Yang YX; Department of Epidemiology and Biostatistics, Center of Clinical Epidemiology and Biostatistics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Crohns Colitis 360 ; 3(2): otab022, 2021 Apr.
Article em En | MEDLINE | ID: mdl-36778941
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article